Search research articles
Contact Us
Filters
Showing results (321-330 of 332) with videos related to
Page
of 34
Sort By:
Swiss Medical Weekly
|
December 5, 2020
Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis
Rahel Schwotzer, Andreas J Flammer, Sabine Gerull, et al.
Blood
|
March 10, 2023
Prospective validation of the prognostic relevance of CD34+CD38- AML stem cell frequency in the HOVON-SAKK132 trial
Lok Lam Ngai, Diana Hanekamp, Fleur Janssen, et al.
Blood Cancer Discovery
|
June 12, 2026
Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
Maximilian Merz, Tomas Jelinek, Thomas Pabst, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 12, 2017
Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group
Diana Averbuch, Gloria Tridello, Jennifer Hoek, et al.
Blood
|
May 1, 2020
Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers
Alexandre Fagnan, Frederik Otzen Bagger, Maria-Riera Piqué-Borràs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 25, 2013
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study
Monique Terwijn, Wim L J van Putten, Angèle Kelder, et al.
Cancers
|
February 10, 2021
Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS
Jeroen Janssen, Bob Löwenberg, Markus Manz, et al.
Haematologica
|
April 2, 2026
Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma
Evgenii Shumilov, Rebecca Wurm-Kuczera, Joseph Kauer, et al.
Frontiers in Immunology
|
December 5, 2015
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death
Abhishek D Garg, Lorenzo Galluzzi, Lionel Apetoh, et al.
Blood Advances
|
February 22, 2021
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
Bob Löwenberg, Thomas Pabst, Johan Maertens, et al.
Page
of 34
Search research articles
Search
Showing results (321-330 of 332) with videos related to
Sort By:
Page
of 34
Swiss Medical Weekly
|
December 5, 2020
Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis
Rahel Schwotzer, Andreas J Flammer, Sabine Gerull, et al.
Blood
|
March 10, 2023
Prospective validation of the prognostic relevance of CD34+CD38- AML stem cell frequency in the HOVON-SAKK132 trial
Lok Lam Ngai, Diana Hanekamp, Fleur Janssen, et al.
Blood Cancer Discovery
|
June 12, 2026
Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
Maximilian Merz, Tomas Jelinek, Thomas Pabst, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 12, 2017
Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group
Diana Averbuch, Gloria Tridello, Jennifer Hoek, et al.
Blood
|
May 1, 2020
Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers
Alexandre Fagnan, Frederik Otzen Bagger, Maria-Riera Piqué-Borràs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 25, 2013
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study
Monique Terwijn, Wim L J van Putten, Angèle Kelder, et al.
Cancers
|
February 10, 2021
Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS
Jeroen Janssen, Bob Löwenberg, Markus Manz, et al.
Haematologica
|
April 2, 2026
Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma
Evgenii Shumilov, Rebecca Wurm-Kuczera, Joseph Kauer, et al.
Frontiers in Immunology
|
December 5, 2015
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death
Abhishek D Garg, Lorenzo Galluzzi, Lionel Apetoh, et al.
Blood Advances
|
February 22, 2021
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
Bob Löwenberg, Thomas Pabst, Johan Maertens, et al.
Page
of 34